LXEO
Lexeo Therapeutics, Inc. Common Stock NASDAQ$5.80
Mkt Cap $429.7M
52w Low $2.43
39.4% of range
52w High $10.99
50d MA $6.29
200d MA $7.06
P/E (TTM)
-3.1x
EV/EBITDA
-49.2x
P/B
12.6x
Debt/Equity
0.0x
ROE
-40.5%
P/FCF
-53.8x
RSI (14)
—
ATR (14)
—
Beta
2.00
50d MA
$6.29
200d MA
$7.06
Avg Volume
927.5K
About
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidat…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.32 | -0.27 | +15.6% | 5.27 | +11.2% | +8.9% | +7.6% | +8.5% | +9.5% | +19.7% | — |
| Nov 5, 2025 | AMC | -0.48 | -0.33 | +31.2% | 8.20 | +0.4% | +2.7% | -0.1% | +3.9% | +11.2% | +12.3% | — |
| Aug 14, 2025 | AMC | -0.64 | -0.60 | +6.2% | 4.79 | +2.5% | -1.5% | +2.7% | -0.2% | +0.2% | -0.2% | — |
| May 12, 2025 | AMC | -0.80 | -0.99 | -23.8% | 2.63 | +0.4% | +7.6% | +2.3% | +2.7% | +23.2% | +25.1% | — |
| Mar 24, 2025 | AMC | -0.87 | -0.78 | +10.3% | 4.09 | +2.4% | +8.6% | -2.4% | +0.5% | +0.2% | -15.2% | — |
| Nov 13, 2024 | AMC | -0.65 | -0.89 | -36.9% | 7.64 | +0.8% | +1.8% | -13.0% | -21.5% | -21.2% | -19.9% | — |
| Aug 12, 2024 | AMC | -0.69 | -0.64 | +7.2% | 11.98 | -0.8% | -2.3% | -2.4% | +1.0% | +1.9% | -0.8% | — |
| May 9, 2024 | AMC | -0.76 | -0.77 | -1.3% | 14.50 | -0.1% | -9.4% | -6.5% | -3.7% | -3.7% | -3.3% | — |
| Mar 11, 2024 | AMC | -0.73 | -0.85 | -16.4% | 14.49 | +3.0% | +8.3% | +14.4% | +8.2% | +7.5% | +8.4% | — |
| Nov 6, 2023 | AMC | -2.60 | -12.36 | -375.4% | 10.50 | +0.0% | -0.4% | +1.3% | +3.3% | +2.7% | +0.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13 | Chardan Capital | Maintains | Buy → Buy | — | $8.12 | $8.11 | -0.1% | -8.5% | -4.9% | -7.6% | -9.0% | -10.6% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.12 | $8.11 | -0.1% | -8.5% | -4.9% | -7.6% | -9.0% | -10.6% |
| Dec 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.73 | $9.75 | +0.2% | +0.7% | +0.4% | +0.3% | +0.0% | -6.4% |
| Nov 5 | Chardan Capital | Maintains | Buy → Buy | — | $8.35 | $8.27 | -1.0% | -1.8% | +0.8% | -1.9% | +2.0% | +9.2% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.22 | $9.23 | +0.1% | +4.1% | +0.1% | -2.4% | +0.1% | +6.7% |
| Oct 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $6.47 | $8.25 | +27.5% | +28.9% | +24.1% | +26.7% | +27.4% | +26.7% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.47 | $8.25 | +27.5% | +28.9% | +24.1% | +26.7% | +27.4% | +26.7% |
| Oct 7 | Chardan Capital | Maintains | Buy → Buy | — | $6.47 | $8.25 | +27.5% | +28.9% | +24.1% | +26.7% | +27.4% | +26.7% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $4.79 | $4.91 | +2.5% | -1.5% | +2.7% | -0.2% | +0.2% | -0.2% |
| Aug 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.79 | $4.91 | +2.5% | -1.5% | +2.7% | -0.2% | +0.2% | -0.2% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LXEO filed a material announcement regarding its genetic medicine pipeline for cardiovascular diseases, likely signaling clinical progress or strategic developments that could significantly impact the company's valuation and clinical-stage risk profile.
Mar 30
8-K · 5.02
!!! Very High
Lexeo Therapeutics, Inc. -- 8-K 5.02: Executive Change
Lexeo Therapeutics' director Adler resigned effective February 1, 2026, representing a leadership change that investors should monitor for potential impacts on company governance and strategic direction.
Feb 5
Data updated apr 25, 2026 8:12pm
· Source: massive.com